应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
IVBIY Innovent Biologics Inc.
休市中 07-18 16:00:00 EDT 延时
资讯
新帖
简况
信达生物全球首创抗VEGF-补体双靶融合蛋白
美通社 · 05-06
信达生物全球首创抗VEGF-补体双靶融合蛋白
荣获七项ASCO口头报告:信达生物IBI363(PD-1/IL-2α-bias)领衔多款管线亮相美国临床肿瘤学会2025年大会
美通社 · 04-23
荣获七项ASCO口头报告:信达生物IBI363(PD-1/IL-2α-bias)领衔多款管线亮相美国临床肿瘤学会2025年大会
头对头帕博利珠单抗,信达生物IBI363(PD-1/IL-2α-bias双特异性抗体融合蛋白)首个关键注册临床研究完成首例受试者给药,用于治疗黑色素瘤
美通社 · 03-03
头对头帕博利珠单抗,信达生物IBI363(PD-1/IL-2α-bias双特异性抗体融合蛋白)首个关键注册临床研究完成首例受试者给药,用于治疗黑色素瘤
信达生物宣布首个中国研发的CTLA-4单抗伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获受理并纳入优先审评
美通社 · 02-23
信达生物宣布首个中国研发的CTLA-4单抗伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获受理并纳入优先审评
信达生物IBI363 (PD-1/IL-2α-bias双特异性抗体融合蛋白) 再获美国FDA快速通道资格认定,治疗鳞状非小细胞肺癌
美通社 · 02-17
信达生物IBI363 (PD-1/IL-2α-bias双特异性抗体融合蛋白) 再获美国FDA快速通道资格认定,治疗鳞状非小细胞肺癌
JPM 2025 | 聚势向前:信达生物迈进双极驱动和全球创新发展新时期
美通社 · 01-17
JPM 2025 | 聚势向前:信达生物迈进双极驱动和全球创新发展新时期
信达生物与奥赛康药业宣布第三代EGFR TKI 肺癌靶向药物奥壹新®(利厄替尼片)获批上市
美通社 · 01-17
信达生物与奥赛康药业宣布第三代EGFR TKI 肺癌靶向药物奥壹新®(利厄替尼片)获批上市
信达生物IBI343 (CLDN 18.2 ADC) 获国家药品监督管理局纳入突破性治疗药物品种,治疗晚期胰腺导管腺癌患者
美通社 · 01-16
信达生物IBI343 (CLDN 18.2 ADC) 获国家药品监督管理局纳入突破性治疗药物品种,治疗晚期胰腺导管腺癌患者
信达生物将出席第43届摩根大通全球医疗健康年会并发表演讲
美通社 · 01-06
信达生物将出席第43届摩根大通全球医疗健康年会并发表演讲
信达生物宣布ROS1抑制剂达伯乐®(己二酸他雷替尼胶囊)获批第二项适应症,用于全线治疗 ROS1 阳性肺癌
美通社 · 01-03
信达生物宣布ROS1抑制剂达伯乐®(己二酸他雷替尼胶囊)获批第二项适应症,用于全线治疗 ROS1 阳性肺癌
信达生物宣布ROS1抑制剂达伯乐®(己二酸他雷替尼胶囊)获国家药品监督管理局批准上市
美通社 · 2024-12-20
信达生物宣布ROS1抑制剂达伯乐®(己二酸他雷替尼胶囊)获国家药品监督管理局批准上市
信达生物与礼来制药深化肿瘤领域合作,达成捷帕力®(匹妥布替尼片)中国大陆商业化协议
美通社 · 2024-12-15
信达生物与礼来制药深化肿瘤领域合作,达成捷帕力®(匹妥布替尼片)中国大陆商业化协议
2024 ESMO Asia | 信达生物口头报告创新型抗CLDN18.2 ADC(IBI343)治疗晚期胰腺癌的I期临床研究数据更新
美通社 · 2024-12-09
2024 ESMO Asia | 信达生物口头报告创新型抗CLDN18.2 ADC(IBI343)治疗晚期胰腺癌的I期临床研究数据更新
信达生物宣布信必乐®(托莱西单抗注射液)新药、耐立克®(奥雷巴替尼)新增适应症成功纳入2024年版国家医保药品目录
美通社 · 2024-11-28
信达生物宣布信必乐®(托莱西单抗注射液)新药、耐立克®(奥雷巴替尼)新增适应症成功纳入2024年版国家医保药品目录
信达生物将在ESMO Asia 2024年会上公布IBI343(CLDN18.2 ADC)等多项创新管线更新临床数据
美通社 · 2024-11-25
信达生物将在ESMO Asia 2024年会上公布IBI343(CLDN18.2 ADC)等多项创新管线更新临床数据
信达生物宣布匹康奇拜单抗(IL-23p19抗体)治疗溃疡性结肠炎的II期临床研究达成主要终点
美通社 · 2024-10-17
信达生物宣布匹康奇拜单抗(IL-23p19抗体)治疗溃疡性结肠炎的II期临床研究达成主要终点
信达生物与奥赛康药业达成第三代EGFR TKI 肺癌靶向药物利厄替尼片(奥壹新®)的战略合作
美通社 · 2024-10-08
信达生物与奥赛康药业达成第三代EGFR TKI 肺癌靶向药物利厄替尼片(奥壹新®)的战略合作
信达生物在2024年欧洲肿瘤内科学会(ESMO)大会公布全球首创PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363联合贝伐珠单抗治疗晚期结直肠癌的临床I期数据
美通社 · 2024-09-18
信达生物在2024年欧洲肿瘤内科学会(ESMO)大会公布全球首创PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363联合贝伐珠单抗治疗晚期结直肠癌的临床I期数据
信达生物在2024年欧洲肿瘤内科学会(ESMO)大会口头报告抗HER2单克隆抗体-喜树碱衍生物偶联物(HER2 ADC)IBI354治疗晚期卵巢癌、乳腺癌等实体瘤的临床数据
美通社 · 2024-09-18
信达生物在2024年欧洲肿瘤内科学会(ESMO)大会口头报告抗HER2单克隆抗体-喜树碱衍生物偶联物(HER2 ADC)IBI354治疗晚期卵巢癌、乳腺癌等实体瘤的临床数据
头对头优效于高剂量度拉糖肽,玛仕度肽糖尿病III期临床研究DREAMS-2结果于EASD口头重磅报告
美通社 · 2024-09-12
头对头优效于高剂量度拉糖肽,玛仕度肽糖尿病III期临床研究DREAMS-2结果于EASD口头重磅报告
加载更多
公司概况
公司名称:
Innovent Biologics Inc.
所属市场:
PINK LIMITED
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"IVBIY","market":"US","secType":"STK","nameCN":"Innovent Biologics Inc.","latestPrice":39.5,"timestamp":1752868800000,"preClose":39.5,"halted":0,"volume":0,"delay":15,"floatShares":407000000,"shares":407000000,"eps":-0.00822,"marketStatus":"休市中","change":0,"latestTime":"07-18 16:00:00 EDT 延时","open":39.5,"high":39.5,"low":39.5,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.00822,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":7,"adr":0,"adrRate":4,"exchange":"PINK LIMITED","adjPreClose":39.5,"volumeRatio":0.029239735303202605},"requestUrl":"/m/hq/s/IVBIY","defaultTab":"news","newsList":[{"id":"2533596248","title":"信达生物全球首创抗VEGF-补体双靶融合蛋白","url":"https://stock-news.laohu8.com/highlight/detail?id=2533596248","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533596248?lang=zh_cn&edition=full","pubTime":"2025-05-06 08:00","pubTimestamp":1746489600,"startTime":"0","endTime":"0","summary":"值得关注的是,全球首个创新型双靶点分子IBI302II期数据显示其高剂量组达到主要研究终点,一年期最佳矫正视力较基线提升10个字母左右,超过80%的受试者能够维持长达12周及以上的给药间隔。\" 关于依莫芙普 依莫芙普是信达生物拥有全球知识产权的一种双特异性重组全人源融合蛋白,研发代号:IBI302。截至目前,信达生物患者援助项目已惠及20余万普通患者,药物捐赠总价值36亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4679597_ZH79597_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IVBIY","LU2328871848.SGD","BK1161","LU1969619763.USD","BK4139","01801","BK1583","LU2488822045.USD","BK1589"],"gpt_icon":0},{"id":"2529693739","title":"荣获七项ASCO口头报告:信达生物IBI363(PD-1/IL-2α-bias)领衔多款管线亮相美国临床肿瘤学会2025年大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2529693739","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529693739?lang=zh_cn&edition=full","pubTime":"2025-04-24 07:00","pubTimestamp":1745449200,"startTime":"0","endTime":"0","summary":"本届 ASCO 年会将于当地时间2025年5月30日-6月3日在美国芝加哥举办。信达生物制药集团高级副总裁周辉博士表示:\"很高兴在本次ASCO大会上,IBI363开发的第一批三大适应症黑色素瘤、肠癌、非小细胞肺癌的临床研究均被接收为口头报告,代表了下一代PD-1双抗肿瘤免疫疗法引起了全球的广泛关注。同时IBI343胰腺癌研究继去年12月ESMO Asia口头报告之后,再次以口头报告登上ASCO舞台。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4671176_ZH71176_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IVBIY","LU1169589451.USD","BK4023","BK1161","BK4139","LU1169590202.USD","01801","PD","LU2488822045.USD","BK1583","BK1589","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":1},{"id":"2516452525","title":"头对头帕博利珠单抗,信达生物IBI363(PD-1/IL-2α-bias双特异性抗体融合蛋白)首个关键注册临床研究完成首例受试者给药,用于治疗黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2516452525","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516452525?lang=zh_cn&edition=full","pubTime":"2025-03-03 08:00","pubTimestamp":1740960000,"startTime":"0","endTime":"0","summary":"目前,IBI363已开出首个关键注册临床研究,用于治疗未经免疫治疗的粘膜型和肢端型黑色素瘤。另外,IBI363已获美国FDA两项快速通道资格认定,分别用于治疗鳞状非小细胞肺癌和黑色素瘤。截至目前,信达生物患者援助项目已惠及20余万普通患者,药物捐赠总","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4631081_ZH31081_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IVBIY","LU2328871848.SGD","PD","BK1161","LU1169589451.USD","LU1169590202.USD","BK4139","LU1969619763.USD","01801","BK1583","LU2488822045.USD","BK4023","BK1589"],"gpt_icon":0},{"id":"2513976262","title":"信达生物宣布首个中国研发的CTLA-4单抗伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2513976262","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513976262?lang=zh_cn&edition=full","pubTime":"2025-02-24 07:52","pubTimestamp":1740354720,"startTime":"0","endTime":"0","summary":"伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗,同时,这也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。研究旨在评估伊匹木单抗联合信迪利单抗新辅助治疗可切除的MSI-H/dMMR结肠癌对比直接根治性手术的有效性和安全性。伊匹木单抗联合信迪利单抗组与信迪利单抗单药组术后病理淋巴结阳性率分别为3.9%与15.9%。伊匹木单抗联合信迪利单抗用于可切除的MSI-H/dMMR结肠癌患者的新辅助治疗的NDA在NMPA优先审评中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4625139_ZH25139_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK4139","CDE","IVBIY","BK4588","BK4008","ALK","BK4500","LU1969619763.USD","01801","BK1589","BK4585","LU2328871848.SGD","LU2488822045.USD","PP","BK4017","BK1583"],"gpt_icon":0},{"id":"2512966214","title":"信达生物IBI363 (PD-1/IL-2α-bias双特异性抗体融合蛋白) 再获美国FDA快速通道资格认定,治疗鳞状非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2512966214","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512966214?lang=zh_cn&edition=full","pubTime":"2025-02-17 08:00","pubTimestamp":1739750400,"startTime":"0","endTime":"0","summary":"旧金山和中国苏州2025年2月17日 /美通社/ -- 信达生物制药集团,一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司,宣布其PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363获得美国食品和药物监督管理局授予快速通道资格,拟定适应症为抗PD-1免疫检查点抑制剂及含铂化疗治疗后进展的局部晚期或转移性鳞状非小细胞肺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4620398_ZH20398_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1169590202.USD","PD","LU2328871848.SGD","BK1583","BK1161","IVBIY","BK4139","LU1169589451.USD","LU1969619763.USD","01801","BK4023","LU2488822045.USD","BK1589"],"gpt_icon":0},{"id":"2504978214","title":"JPM 2025 | 聚势向前:信达生物迈进双极驱动和全球创新发展新时期","url":"https://stock-news.laohu8.com/highlight/detail?id=2504978214","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504978214?lang=zh_cn&edition=full","pubTime":"2025-01-17 08:18","pubTimestamp":1737073080,"startTime":"0","endTime":"0","summary":"成立13年,信达生物快速成长成为一家中国领先的生物制药企业。展望未来,信达生物战略清晰、稳步落地,2025年将是迈入双轮驱动和全球创新发展新时期的重要一年,业务聚势向前、创新力求突破,公司正朝着“成为国际一流的生物制药公司”的愿景稳步迈进。2025年公司有7款药物计划递交新药上市申请或关键临床进行中,7款创新管线计划启动关键注册临床,为公司快速增长持续提供强劲动力。信达生物在不断自","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4597983_ZH97983_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE000M9KFDE8.USD","LU0310799852.SGD","LU2237443465.HKD","LU2264538146.SGD","BK4588","LU0170899867.USD","BK1589","IE00BLSP4452.SGD","IE00BHPRN162.USD","LU1261432733.SGD","LU0320765646.SGD","BK1161","IE0034235295.USD","LU0320765489.SGD","LU1917777945.USD","IE00BKDWB100.SGD","IE00B1XK9C88.USD","LU0787776722.HKD","LU0048584097.USD","LU2023250504.SGD","IE00BWXC8680.SGD","LU0211331839.USD","LU2237443978.SGD","LU0106831901.USD","LU0417517546.SGD","BK4550","BK4585","LU0238689110.USD","BK4207","LU0211327993.USD","LU0683600562.USD","LU2357305700.SGD","LU2242649171.HKD","IE00B775SV38.USD","LU0215105999.USD","IVBIY","LU1119994496.HKD","01801","LU2505996509.AUD","LU0208291251.USD","LU2488822045.USD","BK4566","LU0251132253.USD","LU1244550577.SGD","LU2237443895.HKD","LU1974910355.USD","IE00BDRTCR15.USD","IE00B3S45H60.SGD","LU0976567544.SGD","IE00BJTD4N35.SGD"],"gpt_icon":0},{"id":"2504212978","title":"信达生物与奥赛康药业宣布第三代EGFR TKI 肺癌靶向药物奥壹新®(利厄替尼片)获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2504212978","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504212978?lang=zh_cn&edition=full","pubTime":"2025-01-17 08:00","pubTimestamp":1737072000,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年1月17日 /美通社/ -- 信达生物制药集团,一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司,与奥赛康药业今日联合宣布,第三代表皮生长因子受体酪氨酸激酶抑制剂靶向药物奥壹新的新药上市申请获中国国家药品监督管理局批准上市,用于既往经EGFR-TKI治疗时或治疗后出现疾病进展,并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞肺癌成人患者治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4598259_ZH98259_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","BK1583","BK4211","PFS","BK4195","BK1589","LU1969619763.USD","01801","BK4570","LU2488822045.USD","PPI","LU2328871848.SGD","IVBIY","ORR","BK1161"],"gpt_icon":0},{"id":"2503838069","title":"信达生物IBI343 (CLDN 18.2 ADC) 获国家药品监督管理局纳入突破性治疗药物品种,治疗晚期胰腺导管腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2503838069","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503838069?lang=zh_cn&edition=full","pubTime":"2025-01-16 08:01","pubTimestamp":1736985660,"startTime":"0","endTime":"0","summary":"目前,晚期胰腺癌的治疗主要依赖于系统性化疗。IBI343与表达CLDN18.2的肿瘤细胞结合后,发生CLDN18.2依赖性内化,随后可裂解的连接子降解,从而释放的药物引起DNA损伤,导致肿瘤细胞凋亡。截至目前,IBI343的两项适应症获中国国家药品监督管理局药品评审中心纳入突破性治疗药物品种名单,用于至少接受过二种系统性治疗的CLDN18.2表达阳性的晚期胃/胃食管交界处腺癌,及至少接受过一种系统性治疗的CLDN18.2表达阳性的晚期胰腺导管腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4596993_ZH96993_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IVBIY","ADC","BK4080","LU2328871848.SGD","BK4139","01801","LU1969619763.USD","BK1583","BK1161","LU2488822045.USD","BK1589","BK4231"],"gpt_icon":0},{"id":"2501421763","title":"信达生物将出席第43届摩根大通全球医疗健康年会并发表演讲","url":"https://stock-news.laohu8.com/highlight/detail?id=2501421763","media":"美通社","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501421763?lang=zh_cn&edition=full","pubTime":"2025-01-06 08:00","pubTimestamp":1736121600,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年1月6日 /美通社/ -- 信达生物制药集团,一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司宣布,公司管理层将出席在美国旧金山举办的第43届摩根大通医疗健康年会。摩根大通全球医疗健康年会是全球最负盛名、规模最大的医疗健康投资研讨会之一。截至目前,信达生物患者援助项目已惠及20余万普通患者,药物捐赠总价值36亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4589052_ZH89052_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2237443895.HKD","IVBIY","LU2552382058.USD","BK1589","LU2264538146.SGD","IE00BLSP4452.SGD","LU0215105999.USD","LU2488822045.USD","IE00BDCRKT87.USD","LU0234572021.USD","LU1668664300.SGD","BK4533","LU0971096721.USD","LU2237443382.USD","LU0106831901.USD","LU1244550494.USD","IE00BKVL7J92.USD","LU0882574139.USD","LU1670628061.USD","LU1244550221.USD","LU0238689110.USD","LU1988902786.USD","IE0034235188.USD","LU1720051017.SGD","LU0976567544.SGD","LU2237443549.SGD","LU2237443622.USD","LU1162221912.USD","LU0070302665.USD","LU1032466523.USD","LU0683600562.USD","LU0320765489.SGD","LU0170899867.USD","IE00BLSP4239.USD","LU0251132253.USD","IE00BJTD4V19.USD","LU1894683264.USD","LU2357305700.SGD","LU2328871848.SGD","BK4207","LU0211326839.USD","LU1496350502.SGD","01801","IE00B1XK9C88.USD","BK1161","LU1119994496.HKD","LU0149725797.USD","LU1244550577.SGD","LU1720051108.HKD","IE00BJTD4N35.SGD"],"gpt_icon":0},{"id":"2500132045","title":"信达生物宣布ROS1抑制剂达伯乐®(己二酸他雷替尼胶囊)获批第二项适应症,用于全线治疗 ROS1 阳性肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2500132045","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500132045?lang=zh_cn&edition=full","pubTime":"2025-01-03 08:00","pubTimestamp":1735862400,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年1月3日 /美通社/ -- 信达生物制药集团,一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司宣布,新一代 ROS1 酪氨酸激酶抑制剂达伯乐的第二项新药上市申请获中国国家药品监督管理局批准上市,用于ROS1阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。除此之外,他雷替尼还获得美国FDA授予的用于治疗 ROS1 阳性非小细胞肺癌的孤儿药认定和突破性疗法认定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4587875_ZH87875_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","BK4183","BK4211","LU1969619763.USD","PFS","BK4007","BK4139","IVBIY","LU2488822045.USD","BK1589","BK4195","01801","NUVB","ODD","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2493470395","title":"信达生物宣布ROS1抑制剂达伯乐®(己二酸他雷替尼胶囊)获国家药品监督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2493470395","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493470395?lang=zh_cn&edition=full","pubTime":"2024-12-20 20:08","pubTimestamp":1734696480,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2024年12月20日 /美通社/ -- 信达生物制药集团,一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司宣布,新一代ROS1酪氨酸激酶抑制剂达伯乐的新药上市申请获中国国家药品监督管理局批准上市,用于经ROS1-TKI治疗后进展的ROS1阳性局部晚期或转移性非小细胞肺癌成人患者的治疗。截至目前,信达生物患者援助项目已惠及17余万普通患者,药物捐赠总价值34亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4584619_ZH84619_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01801","LU2328871848.SGD","IVBIY","NUVB","BK4139","BK1583","BK1589","BK4007","BK4183","BK1161","LU2488822045.USD","LU1969619763.USD","ODD"],"gpt_icon":0},{"id":"2491729653","title":"信达生物与礼来制药深化肿瘤领域合作,达成捷帕力®(匹妥布替尼片)中国大陆商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2491729653","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491729653?lang=zh_cn&edition=full","pubTime":"2024-12-16 07:55","pubTimestamp":1734306900,"startTime":"0","endTime":"0","summary":"根据协议,信达生物拥有捷帕力在中国大陆的进口、销售、推广和分销权利,礼来将负责该产品在中国大陆的持续研发和上市后医学事务相关工作。此次合作将充分利用信达生物在血液肿瘤领域丰富的商业化经验及礼来医学团队在血液肿瘤领域丰富的开发经验和科学洞见。双方将强强联手,致力于造福更多中国大陆癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4580201_ZH80201_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01801","LU2488822045.USD","LU0114720955.EUR","SG9999015945.SGD","LU1988902786.USD","LU0203202063.USD","LU2361044865.SGD","SG9999015952.SGD","LU0256863902.USD","LU0471298777.SGD","IVBIY","LU0058720904.USD","LU0882574055.USD","LU2361045086.USD","LU2602419157.SGD","LU2237443549.SGD","LU1127390331.HKD","LU2361044949.HKD","LU0943347566.SGD","SG9999001176.SGD","LU2237443978.SGD","IE00BJLML261.HKD","LU1868836757.USD","IE00B1BXHZ80.USD","SG9999014898.SGD","LU0672654240.SGD","LU0238689110.USD","LU0061475181.USD","SGXZ81514606.USD","LU0094547139.USD","IE00B2B36J28.USD","LU2063271972.USD","BK4588","BK1583","SG9999017495.SGD","LLY","LU0471298694.HKD","LU0823416689.USD","LU1917777945.USD","LU0097036916.USD","SG9999015986.USD","SG9999018857.SGD","LU2360106947.USD","LU0006306889.USD","BK4533","LU0109391861.USD","LU2237438978.USD","LU1061106388.HKD","LU1035775433.USD","LU1064131342.USD"],"gpt_icon":1},{"id":"2490709174","title":"2024 ESMO Asia | 信达生物口头报告创新型抗CLDN18.2 ADC(IBI343)治疗晚期胰腺癌的I期临床研究数据更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2490709174","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490709174?lang=zh_cn&edition=full","pubTime":"2024-12-09 08:00","pubTimestamp":1733702400,"startTime":"0","endTime":"0","summary":"在扩大样本量的CLDN18.2表达阳性的既往经治的胰腺癌晚期患者中,IBI343进一步展示出了令人鼓舞的早期疗效数据和良好的安全性。在中国,2022年胰腺癌新发病例达12万,死亡病例11万。未发生TEAE导致的死亡。希望IBI343的临床推动,能够为全球患者带来突破性的治疗。作为创新型TOPO1i型ADC,IBI343在临床I期研究中展现出可控的安全性和令人鼓舞的疗效性信号,目前正在胃癌和胰腺癌等瘤种上探索IBI343的治疗潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4573831_ZH73831_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IVBIY","ADC","BK4080","LU2328871848.SGD","BK4139","01801","LU1969619763.USD","BK1583","BK1161","LU2488822045.USD","BK1589","BK4231"],"gpt_icon":0},{"id":"2486035641","title":"信达生物宣布信必乐®(托莱西单抗注射液)新药、耐立克®(奥雷巴替尼)新增适应症成功纳入2024年版国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486035641","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486035641?lang=zh_cn&edition=full","pubTime":"2024-11-28 12:05","pubTimestamp":1732766700,"startTime":"0","endTime":"0","summary":"新版国家医保目录将于2025年1月1日起正式实施。此次,信必乐新药纳入国家医保目录,用于治疗原发性高胆固醇血症和混合型血脂异常的成人患者。同时,耐立克新增适应症纳入国家医保目录,将使得更广泛的CML患者获益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4567879_ZH67879_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","LU2488822045.USD","LU1969619763.USD","CVM","BK1589","IVBIY","BK4139","BK1583","LU2328871848.SGD","01801"],"gpt_icon":0},{"id":"2486725493","title":"信达生物将在ESMO Asia 2024年会上公布IBI343(CLDN18.2 ADC)等多项创新管线更新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2486725493","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486725493?lang=zh_cn&edition=full","pubTime":"2024-11-25 08:16","pubTimestamp":1732493760,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2024年11月25日 /美通社/ -- 信达生物制药集团,一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司,今日宣布,将在2024年欧洲肿瘤内科学会亚洲年会上公布近10项临床数据,含2项口头报告,其中包括IBI343治疗胰腺癌的I期更新数据。ESMO Asia年会将于当地时间2024年12月6日-8日在新加坡举办。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4564278_ZH64278_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2328871848.SGD","BK1161","ADC","LU1969619763.USD","01801","LU2488822045.USD","BK1589","BK4080","BK4139","BK1583","IVBIY","BK4231"],"gpt_icon":0},{"id":"2476251188","title":"信达生物宣布匹康奇拜单抗(IL-23p19抗体)治疗溃疡性结肠炎的II期临床研究达成主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2476251188","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476251188?lang=zh_cn&edition=full","pubTime":"2024-10-17 08:00","pubTimestamp":1729123200,"startTime":"0","endTime":"0","summary":"我很高兴看到匹康奇拜单抗治疗中重度活动性溃疡性结肠II期临床研究中达成主要终点,受试者获得显著的诱导期临床获益,同时安全性良好。近年来,以IL-23为靶点的新一代药物因其在溃疡性结肠炎患者治疗中卓越的疗效和良好的安全性引发关注;目前,国内市场上尚无IL-23p19靶点药物获批治疗溃疡性结肠炎,本研究是第一个由国内企业自主研发的IL-23p19单抗治疗溃疡性结肠炎的临床研究。溃疡性结肠炎严重威胁身体健康并对日常生活和心理带来影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4532408_ZH32408_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","IBD","BK1161","LU2488822045.USD","BK1589","01801","LU1969619763.USD","LU2328871848.SGD","BK4139","IVBIY"],"gpt_icon":0},{"id":"2473459176","title":"信达生物与奥赛康药业达成第三代EGFR TKI 肺癌靶向药物利厄替尼片(奥壹新®)的战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2473459176","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473459176?lang=zh_cn&edition=full","pubTime":"2024-10-08 08:00","pubTimestamp":1728345600,"startTime":"0","endTime":"0","summary":"利厄替尼是具有自主知识产权、全新分子实体、活性显著的口服的第三代EGFR-TKI。我们与奥赛康在利厄替尼片(奥壹新)的合作有望给广大的EGFR突变肺癌患者提供一个创新靶向药物,同时这将进一步提升信达生物在肿瘤治疗领域的领先地位。2024年10月,信达生物与奥赛康就利厄替尼片在中国达成独家商业化合作。截至目前,信达生物患者援助项目已惠及17余万普通患者,药物捐赠总价值34亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4518499_ZH18499_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1969619763.USD","01801","BK1583","BK4139","BK1589","PFS","CNS","BK4211","IVBIY","BK1161","BK4195","PPI","LU2328871848.SGD","BK4570","BK4135","LU2488822045.USD"],"gpt_icon":0},{"id":"2468317176","title":"信达生物在2024年欧洲肿瘤内科学会(ESMO)大会公布全球首创PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363联合贝伐珠单抗治疗晚期结直肠癌的临床I期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2468317176","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468317176?lang=zh_cn&edition=full","pubTime":"2024-09-18 08:00","pubTimestamp":1726617600,"startTime":"0","endTime":"0","summary":"PD-1/IL-2α-bias双特异性抗体融合蛋白联合贝伐珠单抗治疗晚期结直肠癌的I期临床数据 本次研究数据来自一项I期临床研究,旨在评估IBI363联合贝伐珠单抗治疗晚期结直肠癌受试者的安全性、耐受性和初步有效性。IBI363联合贝伐珠单抗与IBI363单药相比,安全谱类似,未发现新的安全性风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4508243_ZH08243_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","BK4023","IVBIY","LU1169590202.USD","01801","LU1169589451.USD","LU2488822045.USD","PD","BK1589","BK1583","LU2328871848.SGD","BK1161","LU1969619763.USD"],"gpt_icon":0},{"id":"2468171753","title":"信达生物在2024年欧洲肿瘤内科学会(ESMO)大会口头报告抗HER2单克隆抗体-喜树碱衍生物偶联物(HER2 ADC)IBI354治疗晚期卵巢癌、乳腺癌等实体瘤的临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2468171753","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468171753?lang=zh_cn&edition=full","pubTime":"2024-09-18 08:00","pubTimestamp":1726617600,"startTime":"0","endTime":"0","summary":"共368例晚期实体瘤受试者接受了不同剂量的IBI354单药治疗,包括178例乳腺癌、92例卵巢癌、38例结直肠癌及60例其他肿瘤的受试者。HER2靶点作为一个成熟靶点,针对HER2的靶向治疗在乳腺癌和胃癌中已被证实具有较好的疗效。已有临床数据提示IBI354在乳腺癌人群具有充分的开发前景。IBI354作为抗HER2单克隆抗体-喜树碱衍生物偶联物,初步研究结果提示在HER2阳性消化系统恶性肿癌观察到积极的疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4508244_ZH08244_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","BK1589","BK4139","LU1969619763.USD","BK4080","BK4231","ADC","LU2488822045.USD","BK1161","01801","IVBIY","LU2328871848.SGD"],"gpt_icon":0},{"id":"2466293608","title":"头对头优效于高剂量度拉糖肽,玛仕度肽糖尿病III期临床研究DREAMS-2结果于EASD口头重磅报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2466293608","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466293608?lang=zh_cn&edition=full","pubTime":"2024-09-12 08:00","pubTimestamp":1726099200,"startTime":"0","endTime":"0","summary":"同时,玛仕度肽首个减重三期临床GLORY-1研究结果也于本次大会作口头汇报。整体安全性特征与玛仕度肽既往临床研究一致,未发现新增安全性信号。玛仕度肽对比度拉糖肽联合口服降糖药治疗在中国2型糖尿病受试者的3期研究取得成功,其结果在今年EASD大会以口头报告披露,证明了玛仕度肽在血糖控制、减重以及多种代谢指标方面的综合获益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4503608_ZH03608_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01801","IVBIY","LU2328871848.SGD","III","LU1969619763.USD","BK1583","BK4134","LU2488822045.USD","BK4139","BK1161","BK1589"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"ytd","weight":0}],"exchange":"PINK LIMITED","name":"Innovent Biologics Inc.","nameEN":"Innovent Biologics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Innovent Biologics Inc.(IVBIY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Innovent Biologics Inc.(IVBIY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Innovent Biologics Inc.,IVBIY,Innovent Biologics Inc.股票,Innovent Biologics Inc.股票老虎,Innovent Biologics Inc.股票老虎国际,Innovent Biologics Inc.行情,Innovent Biologics Inc.股票行情,Innovent Biologics Inc.股价,Innovent Biologics Inc.股市,Innovent Biologics Inc.股票价格,Innovent Biologics Inc.股票交易,Innovent Biologics Inc.股票购买,Innovent Biologics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Innovent Biologics Inc.(IVBIY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Innovent Biologics Inc.(IVBIY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}